From the publishers of JADPRO
Updates for the Advanced Practitioner
HER2-Positive Breast Cancer
Subscribe
About
Contact
MENU
Home
Visit JADPRO Online
In The News
In The Literature
Videos
More Updates
Advertisement
In The News
The ASCO Post
Researchers Find Evidence-Based Radiation Treatment After Lumpectomy Leads to High-Quality, High-Value Care
MedicalXpress
Researchers Discover Key to Drug Resistance in Common Breast Cancer Treatment
OncLive
Age and Subtype Impact Outcomes More Than Surgical Extent in Breast Cancer
OncLive
Neoadjuvant Therapy Fundamental in Triple-Negative and HER2-Positive Breast Cancer
BreastCancer.org
Kisqali Approved by FDA to Treat Hormone-Receptor-Positive, Advanced-Stage Disease
BreastCancer.org
In Patients With Diabetes, Metformin is Linked to Improved Outcomes in Patients With HER2-Positive, Hormone-Receptor-Positive Breast Cancer
Cancer Network
HER2 Guidelines for Breast Cancer Could Misclassify Some Patients
Cure Today
Neoadjuvant Treatment Options May Improve Chances of Breast Conservation
The ASCO Post
Veliparib Improves Reponse but Not Progression-Free Survival in BRCA-Mutation Carriers
MedicalXpress
Women Who Have a False-Positive Screening Mammogram Are More Likely to Delay Their Next Screening
MedscapeNews
Genetic Testing Not Offered Enough to Breast Cancer Patients
OncLive
Olaparib Improves PFS in Phase III BRCA-Positive/HER2-Negative Breast Cancer Trial
OncLive
Breast Density Surpasses Other Risk Factors in Development of Breast Cancer
ReachMD
Women With Menopausal Symptoms More Likely to Stop Preventive Therapy
BreastCancer.org
Breast Cancer Treatment Causes Severe Side Effects in Many Women
BreastCancer.org
Women Treated for DCIS Live Longer Than Women With No History of DCIS
OncLive.com
Neoadjuvant Abemaciclib Active in HER2-Positive/HR-Negative Breast Cancer
The ASCO Post
BRCA Status Does Not Seem to Affect Survival Outcomes in Young Women With Early Breast Cancer
Targeted Oncology
Nab-Paclitaxel Shows Greater Benefit Than Paclitaxel in Breast Cancer Subsets
Cancer Network
Increased TIL Levels Associated With Better Outcomes in Patients With HER2-Positive Breast Cancer
Medscape.com
In HER2-Negative Breast Cancer, Brain Mets Are HER2-Positive 20% of the Time
Practice Update
Vinorelbine With Pertuzumab and Trastuzumab as First-Line Treatment in Patients With HER2-Positive Breast Cancer
OncLive.com
Prophylactic Treatment Reduces Neratinib-Related Toxicity in HER2-Positive Breast Cancer
News Medical Net
HER2-Targeted Dendritic Cell Vaccine Shows Promise for Treating Patients with Early-Stage Breast Cancer
CancerNetwork.com
T-DM1 Offers Similar PFS, More Tolerable in Advanced HER2-Positive Breast Cancer
MedicalXpress
Innovative Drug May Revolutionize the Treatment of Early-Stage Breast Cancer
Science Daily
Rare HER2 Mutations May Not Always Spur Breast Cancers on Their Own
MedicalXpress
Higher Vitamin D Levels Associated with Better Outcomes in Breast Cancer Survivors
CancerNetwork.com
Elevated Troponin Levels Associated with Trastuzumab-Related Cardiac Dysfunction
Breast Cancer News
One-Third of People Diagnosed With Breast Cancer Not Getting Appropriate Follow-Up Imaging
MedPage Today
Benefits of Bone-Modifying Agents Confirmed in Breast Cancer
Science Daily
New Standard Helps Ensure Accurate Clinical Measurements of HER2 Breast Cancer Gene
MedicalXpress
Breast Cancer Cells Found to Switch Molecular Characteristics
MedPage Today
Breast Cancer: Ovarian Suppression Benefits High-Risk Premenopausal Patients
Medical News Today
Study Demonstrates How Breast Cancers Use White Blood Cells to Avoid Immune Defenses and Promote Growth
Science Daily
Updated Testing Guidelines Make More Women Eligible for Herceptin, Yet Benefit Uncertain
Oncology Nursing Forum
The Nurse Practitioner Role in Oncology: Advancing Patient Care
Breast Cancer.Org
Anthracycline Chemo Regimen Seems Better Than Regimen Without Anthracycline for Early-Stage, HER2-Negative, High-Risk Disease
The ASCO Post
Results of Two Pivotal Breast Cancer Trials Confirmed the Practice-Changing Findings that Resulted from Earlier Findings
The ASCO Post
Meta-analysis Indicates Similar Outcomes With Neoadjuvant Endocrine vs Chemotherapy in Estrogen Receptor–Positive Breast Cancer
Oncology Nurse Advisor
New Drug Combination Before Surgery May Improve Outcomes for Advanced HER2+ Breast Cancer
MedicalXpress
New Breast Cancer Staging System Emphasizes Importance of Tumor Biology as Prognostic Indicator
The ASCO Post
Hope S. Rugo, MD, on HER2+ Breast Cancer: Findings on a Trastuzumab Biosimilar
Breast Cancer.org
Best Surgery for Early-Stage Disease May Depend on Age
The ASCO Post
Meta-Aanalysis of Breast Cancer Studies Demonstrates Value of Pathologic Complete Response
The ASCO Post
Young Women Require Formal Assessment to Identify Breast Cancer Risk
Oncology Nurse Advisor
Presurgical Treatment in HER2-Positive Breast Cancer Achieves Significant Reduction in Disease
Cancer Research
SABCS Abstract OT3-01-04: An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)
Cancer Therapy Advisor
Plenary Lecture at SABCS: Researchers Continue to Explore HER2 Blockade Strategies
The ASCO Post
Ado-Trastuzumab Emtansine Improved Overall Survival for Heavily Pretreated Patients With HER2-Positive Breast Cancer
Videos
Perspectives on the Collaborative Management of HER2-Positive Breast Cancer
Advertisement
Videos
Perspectives on the Collaborative Management of HER2-Positive Breast Cancer
Advertisement
Copyright © 2019 Harborside Press, LLC All rights reserved.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our
Privacy Policy
to learn more.